Stay updated with breaking news from Invitae. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Invitae Co. (NYSE:NVTA – Get Rating) – Equities research analysts at SVB Leerink raised their Q2 2023 earnings per share (EPS) estimates for shares of Invitae in a note issued to investors on Tuesday, May 9th. SVB Leerink analyst P. Souda now anticipates that the medical research company will post earnings per share of ($0.34) […] ....
Shares of Invitae Co. (NYSE:NVTA – Get Rating) have been assigned an average rating of “Hold” from the twelve research firms that are currently covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a sell rating and six have assigned a hold rating to the company. The average 1-year price […] ....
Invitae (NYSE:NVTA – Get Rating) and Biodesix (NASDAQ:BDSX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership. Insider and Institutional Ownership 76.8% of Invitae shares are owned by […] ....
Invitae Co. (NYSE:NVTA – Get Rating) has earned a consensus recommendation of “Hold” from the twelve analysts that are covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a sell recommendation and six have issued a hold recommendation on the company. The average 12 month price objective among analysts that have […] ....
Shares of Invitae Co. (NYSE:NVTA – Get Rating) have been assigned an average recommendation of “Hold” from the twelve research firms that are covering the company, MarketBeat.com reports. Five analysts have rated the stock with a sell recommendation and six have issued a hold recommendation on the company. The average 1 year price target among […] ....